Hidden

AN INTRAVAGINAL RING FOR THE TREATMENT OF ENDOMETRIOSIS AND UTERINE FIBROIDS

Approximately 10% of all American women in the reproductive age suffer from moderate to severe endometriosis. 20% of these women (1.2 million) are ideal candidates for treatment with gonadotropin-releasing hormones (GnRH) agonists such as Leuprolide. Currently, these drugs are administered as monthly subcutaneous injections. Based on several analyst reports, we believe that the GnRH agonist market is greater than $1 billion in annual sales. 

 Auritec Pharmaceuticals has formulated a GnRH agonist intravaginal ring (IVR) which may improve compliance and ease of use in women suffering from endometriosis and uterine fibroids. This IVR has been tested in vitro and in vivo and has shown sustained-release for 4 weeks. It is being further developed for a first-in-human clinical trial.

IN VITRO RELEASE DATA FOR 1-MONTH

 

 

 

 

 

 

 

 

IN VIVO RELEASE DATA IN SHEEP FOR 1-MONTH